论文部分内容阅读
尽管急性心肌梗塞的治疗有了很大进展,但大系列随机临床研究报告6小时内溶纤的早期(30～35)死亡率仍为6～9％。从实际出发,危险的数学计算应包括临床有代表性患者中选出各种有关的预后指标。本文采用GUSTO-Ⅰ试验组在15个国家、1081所医院41021例的大系列研究中,综合分析基础临床资料与溶纤后30天内死亡的关系,并从患者来院时的表现中发展了一种多因子的统计学模型用于可能有溶栓指标病人的处理。 方法与结果 GUSTO-Ⅰ试验组的41021例病人随机分成四组:链激酶+皮下肝素、链激酶+静脉肝素、t-PA+静脉肝素和t-
Although great progress has been made in the treatment of acute myocardial infarction, a large series of randomized clinical studies report that the early (30-35) mortality of fibrinolytic fibroids remains 6 to 9% within 6 hours. In practical terms, the dangerous mathematical calculations should include the selection of various relevant prognostic indicators in clinically representative patients. In the present study, GUSTO-I trial was used to analyze the relationship between basic clinical data and death within 30 days after fibrinolysis in a large series of 41021 cases in 1081 hospitals in 15 countries and to develop a A multi-factor statistical model was used in the treatment of patients who may have thrombolytic markers. Methods and Results Forty-one to twenty-one patients in the GUSTO-I trial were randomly divided into four groups: streptokinase + subcutaneous heparin, streptokinase + heparin, t-PA + venous heparin and t-